{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T12:20:38Z","timestamp":1793622038293,"version":"4.5.0"},"reference-count":47,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Diffuse large B-cell lymphoma (DLBCL) patients are typically treated with immunochemotherapy containing rituximab (rituximab, cyclophosphamide, hydroxydaunorubicin-vincristine (Oncovin), and prednisone [R-CHOP]); however, prognosis is extremely poor if R-CHOP fails. To identify genetic mechanisms contributing to primary or acquired R-CHOP resistance, we performed target-panel sequencing of 135 relapsed\/refractory DLBCLs (rrDLBCLs), primarily comprising circulating tumor DNA from patients on clinical trials. Comparison with a metacohort of 1670 diagnostic DLBCLs identified 6 genes significantly enriched for mutations upon relapse. TP53 and KMT2D were mutated in the majority of rrDLBCLs, and these mutations remained clonally persistent throughout treatment in paired diagnostic-relapse samples, suggesting a role in primary treatment resistance. Nonsense and missense mutations affecting MS4A1, which encodes CD20, are exceedingly rare in diagnostic samples but show recurrent patterns of clonal expansion following rituximab-based therapy. MS4A1 missense mutations within the transmembrane domains lead to loss of CD20 in vitro, and patient tumors harboring these mutations lacked CD20 protein expression. In a time series from a patient treated with multiple rounds of therapy, tumor heterogeneity and minor MS4A1-harboring subclones contributed to rapid disease recurrence, with MS4A1 mutations as founding events for these subclones. TP53 and KMT2D mutation status, in combination with other prognostic factors, may be used to identify high-risk patients prior to R-CHOP for posttreatment monitoring. Using liquid biopsies, we show the potential to identify tumors with loss of CD20 surface expression stemming from MS4A1 mutations. Implementation of noninvasive assays to detect such features of acquired treatment resistance may allow timely transition to more effective treatment regimens.<\/jats:p>","DOI":"10.1182\/bloodadvances.2020001696","type":"journal-article","created":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:43:14Z","timestamp":1593229394000},"page":"2886-2898","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":120,"title":["Genetic and evolutionary patterns of treatment resistance in relapsed B-cell lymphoma"],"prefix":"10.1182","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6306-9361","authenticated-orcid":false,"given":"Christopher K.","family":"Rushton","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5341-7868","authenticated-orcid":false,"given":"Sarah E.","family":"Arthur","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"},{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Alcaide","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Cheung","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aixiang","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"},{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1309-4873","authenticated-orcid":false,"given":"Krysta M.","family":"Coyle","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6200-4945","authenticated-orcid":false,"given":"Kirstie L. S.","family":"Cleary","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Thomas","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6413-6586","authenticated-orcid":false,"given":"Laura K.","family":"Hilton","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil","family":"Michaud","sequence":"first","affiliation":[{"name":"Epizyme, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Daigle","sequence":"first","affiliation":[{"name":"Epizyme, Cambridge, MA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jordan","family":"Davidson","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bushell","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Yu","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan N.","family":"Rys","sequence":"first","affiliation":[{"name":"McGill University, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7789-1257","authenticated-orcid":false,"given":"Michael","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lois","family":"Shepherd","sequence":"first","affiliation":[{"name":"Canadian Cancer Trials Group, Queen's University, Kingston, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7146-7175","authenticated-orcid":false,"given":"Marco A.","family":"Marra","sequence":"first","affiliation":[{"name":"Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Kuruvilla","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Crump","sequence":"first","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, ON, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koren","family":"Mann","sequence":"first","affiliation":[{"name":"Lady Davis Institute for Medical Research,"},{"name":"Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarit","family":"Assouline","sequence":"first","affiliation":[{"name":"Jewish General Hospital, Montreal, QC, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Connors","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Steidl","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2077-089X","authenticated-orcid":false,"given":"Mark S.","family":"Cragg","sequence":"first","affiliation":[{"name":"Faculty of Medicine, University of Southampton, Southampton, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W.","family":"Scott","sequence":"first","affiliation":[{"name":"Centre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie A.","family":"Johnson","sequence":"first","affiliation":[{"name":"McGill University, Montreal, QC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2932-7800","authenticated-orcid":false,"given":"Ryan D.","family":"Morin","sequence":"first","affiliation":[{"name":"Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, BC, Canada;"},{"name":"Genome Sciences Centre, BC Cancer, Vancouver, BC, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,6,26]]},"reference":[{"issue":"10","key":"2020062611393589200_B1","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1200\/JCO.2013.51.5866","article-title":"Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"32","author":"Maurer","year":"2014","journal-title":"J Clin Oncol"},{"issue":"11","key":"2020062611393589200_B2","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1182\/blood-2002-11-3442","article-title":"Rituximab plus CHOP (R-CHOP) overcomes bcl-2\u2013associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)","volume":"101","author":"Mounier","year":"2003","journal-title":"Blood"},{"issue":"5","key":"2020062611393589200_B3","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00277-014-2271-1","article-title":"Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy","volume":"94","author":"Rovira","year":"2015","journal-title":"Ann Hematol"},{"issue":"16","key":"2020062611393589200_B4","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study [published correction appears in Blood. 2018;131(5):587-588]","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"11","key":"2020062611393589200_B5","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3390\/cancers10110459","article-title":"Mutational evolution in relapsed diffuse large B-cell lymphoma","volume":"10","author":"Nijland","year":"2018","journal-title":"Cancers (Basel)"},{"issue":"9","key":"2020062611393589200_B6","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1158\/1078-0432.CCR-15-2123","article-title":"Genetic landscapes of relapsed and refractory diffuse large B-cell lymphomas","volume":"22","author":"Morin","year":"2016","journal-title":"Clin Cancer Res"},{"issue":"3","key":"2020062611393589200_B7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1002\/gcc.22328","article-title":"Whole exome sequencing of relapsed\/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma","volume":"55","author":"Mareschal","year":"2016","journal-title":"Genes Chromosomes Cancer"},{"issue":"18","key":"2020062611393589200_B8","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1182\/blood-2013-01-479865","article-title":"Analysis of FOXO1 mutations in diffuse large B-cell lymphoma","volume":"121","author":"Trinh","year":"2013","journal-title":"Blood"},{"issue":"19","key":"2020062611393589200_B9","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1182\/blood-2012-05-433334","article-title":"Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study","volume":"120","author":"Xu-Monette","year":"2012","journal-title":"Blood"},{"issue":"7","key":"2020062611393589200_B10","doi-asserted-by":"crossref","first-page":"1381","DOI":"10.1002\/ijc.30838","article-title":"TP53 mutation and survival in aggressive B cell lymphoma","volume":"141","author":"Zenz","year":"2017","journal-title":"Int J Cancer"},{"issue":"59","key":"2020062611393589200_B11","doi-asserted-by":"crossref","first-page":"99237","DOI":"10.18632\/oncotarget.18502","article-title":"Comparative analysis of primary versus relapse\/refractory DLBCL identifies shifts in mutation spectrum","volume":"8","author":"Greenawalt","year":"2017","journal-title":"Oncotarget"},{"issue":"32","key":"2020062611393589200_B12","doi-asserted-by":"crossref","first-page":"51494","DOI":"10.18632\/oncotarget.9860","article-title":"Clonal evolution in relapsed and refractory diffuse large B-cell lymphoma is characterized by high dynamics of subclones","volume":"7","author":"Melchardt","year":"2016","journal-title":"Oncotarget"},{"issue":"1","key":"2020062611393589200_B13","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1373\/clinchem.2012.196014","article-title":"Cancer genome scanning in plasma: detection of tumor-associated copy number aberrations, single-nucleotide variants, and tumoral heterogeneity by massively parallel sequencing","volume":"59","author":"Chan","year":"2013","journal-title":"Clin Chem"},{"issue":"10","key":"2020062611393589200_B14","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1002\/ijc.30650","article-title":"Analysis of ctDNA to predict prognosis and monitor treatment responses in metastatic pancreatic cancer patients","volume":"140","author":"Cheng","year":"2017","journal-title":"Int J Cancer"},{"issue":"28","key":"2020062611393589200_B15","doi-asserted-by":"crossref","first-page":"2845","DOI":"10.1200\/JCO.2018.78.5246","article-title":"Circulating tumor DNA measurements as early outcome predictors in diffuse large B-cell lymphoma","volume":"36","author":"Kurtz","year":"2018","journal-title":"J Clin Oncol"},{"issue":"3","key":"2020062611393589200_B16","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10555-016-9629-x","article-title":"Origins, structures, and functions of circulating DNA in oncology","volume":"35","author":"Thierry","year":"2016","journal-title":"Cancer Metastasis Rev"},{"issue":"4","key":"2020062611393589200_B17","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1038\/nrc.2017.7","article-title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","volume":"17","author":"Wan","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"5","key":"2020062611393589200_B18","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/nm.3519","article-title":"An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage","volume":"20","author":"Newman","year":"2014","journal-title":"Nat Med"},{"issue":"14","key":"2020062611393589200_B19","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1182\/blood-2016-05-719641","article-title":"Diffuse large B-cell lymphoma genotyping on the liquid biopsy","volume":"129","author":"Rossi","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2020062611393589200_B20","doi-asserted-by":"crossref","first-page":"11815","DOI":"10.1038\/ncomms11815","article-title":"Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients [published correction appears in Nat Commun. 2016;7:13513]","volume":"7","author":"Chabon","year":"2016","journal-title":"Nat Commun"},{"issue":"1","key":"2020062611393589200_B21","doi-asserted-by":"crossref","first-page":"8760","DOI":"10.1038\/ncomms9760","article-title":"Multifocal clonal evolution characterized using circulating tumour DNA in a case of metastatic breast cancer","volume":"6","author":"Murtaza","year":"2015","journal-title":"Nat Commun"},{"issue":"2","key":"2020062611393589200_B22","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1182\/blood-2016-02-699520","article-title":"Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma","volume":"128","author":"Assouline","year":"2016","journal-title":"Blood"},{"issue":"8","key":"2020062611393589200_B23","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1038\/s41592-018-0051-x","article-title":"Strelka2: fast and accurate calling of germline and somatic variants","volume":"15","author":"Kim","year":"2018","journal-title":"Nat Methods"},{"issue":"2","key":"2020062611393589200_B24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.cell.2017.09.027","article-title":"Genetic and functional drivers of diffuse large B cell lymphoma","volume":"171","author":"Reddy","year":"2017","journal-title":"Cell"},{"issue":"15","key":"2020062611393589200_B25","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"5","key":"2020062611393589200_B26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes [published corrections appears in Nat Med. 2018;24(8):1292; Nat Med. 2018;24(8):1290-1291]","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"1","key":"2020062611393589200_B27","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1038\/s41467-018-06354-3","article-title":"Genome-wide discovery of somatic regulatory variants in diffuse large B-cell lymphoma","volume":"9","author":"Arthur","year":"2018","journal-title":"Nat Commun"},{"issue":"20","key":"2020062611393589200_B28","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1182\/blood.2019003535","article-title":"Targeted sequencing in DLBCL, molecular subtypes, and outcomes: a Haematological Malignancy Research Network report","volume":"135","author":"Lacy","year":"2020","journal-title":"Blood"},{"issue":"4","key":"2020062611393589200_B29","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","article-title":"A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications","volume":"37","author":"Wright","year":"2020","journal-title":"Cancer Cell"},{"issue":"10","key":"2020062611393589200_B30","first-page":"3999","article-title":"Antibody distance from the cell membrane regulates antibody effector mechanisms","volume":"198","author":"Cleary","year":"2017","journal-title":"J Immunol Baltim Md 1950"},{"issue":"7360","key":"2020062611393589200_B31","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"issue":"1","key":"2020062611393589200_B32","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/cdd.2017.180","article-title":"Why are there hotspot mutations in the TP53 gene in human cancers?","volume":"25","author":"Baugh","year":"2018","journal-title":"Cell Death Differ"},{"key":"2020062611393589200_B33","doi-asserted-by":"crossref","first-page":"D941","DOI":"10.1093\/nar\/gky1015","article-title":"COSMIC: the Catalogue Of Somatic Mutations In Cancer","volume":"47","author":"Tate","year":"2019","journal-title":"Nucleic Acids Res"},{"issue":"10","key":"2020062611393589200_B34","doi-asserted-by":"crossref","first-page":"2382","DOI":"10.1158\/1535-7163.MCT-15-0077","article-title":"NSCLC driven by DDR2 mutation is sensitive to dasatinib and JQ1 combination therapy","volume":"14","author":"Xu","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"2020062611393589200_B35","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2018-99-120089","article-title":"Haploinsufficiency for NR3C1 drives glucocorticoid resistance by inactivation the PI3K\/AKT\/GSK3\u03b2\/Bim pathway in adult acute lymphoblastic leukemia [abstract]","volume":"132","author":"Haowen","year":"2018","journal-title":"Blood"},{"issue":"6","key":"2020062611393589200_B36","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1097\/01.ftd.0000184162.60197.c1","article-title":"Pharmacokinetic behavior of rituximab: a study of different schedules of administration for heterogeneous clinical settings","volume":"27","author":"Regazzi","year":"2005","journal-title":"Ther Drug Monit"},{"issue":"1","key":"2020062611393589200_B37","first-page":"114","article-title":"P53 is required for doxorubicin-induced apoptosis via the TGF-beta signaling pathway in osteosarcoma-derived cells","volume":"6","author":"Sun","year":"2015","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2020062611393589200_B38","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13058-018-1044-5","article-title":"Breast cancer survival predicted by TP53 mutation status differs markedly depending on treatment","volume":"20","author":"Ungerleider","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"3","key":"2020062611393589200_B39","doi-asserted-by":"crossref","first-page":"e1108","DOI":"10.1038\/cddis.2014.75","article-title":"Unequal prognostic potentials of p53 gain-of-function mutations in human cancers associate with drug-metabolizing activity","volume":"5","author":"Xu","year":"2014","journal-title":"Cell Death Dis"},{"issue":"10","key":"2020062611393589200_B40","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/nm.3940","article-title":"Disruption of KMT2D perturbs germinal center B cell development and promotes lymphomagenesis","volume":"21","author":"Zhang","year":"2015","journal-title":"Nat Med"},{"issue":"10","key":"2020062611393589200_B41","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/nm.3943","article-title":"The histone lysine methyltransferase KMT2D sustains a gene expression program that represses B cell lymphoma development","volume":"21","author":"Ortega-Molina","year":"2015","journal-title":"Nat Med"},{"issue":"3","key":"2020062611393589200_B42","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.18.01583","article-title":"Double-hit gene expression signature defines a distinct subgroup of germinal center B-cell-like diffuse large B-cell lymphoma","volume":"37","author":"Ennishi","year":"2019","journal-title":"J Clin Oncol"},{"issue":"25","key":"2020062611393589200_B43","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2016-03-635219","article-title":"Dynamic monitoring of circulating tumor DNA in non-Hodgkin lymphoma","volume":"127","author":"Roschewski","year":"2016","journal-title":"Blood"},{"issue":"3","key":"2020062611393589200_B44","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3324\/haematol.2008.001024","article-title":"CD20 mutations involving the rituximab epitope are rare in diffuse large B-cell lymphomas and are not a significant cause of R-CHOP failure","volume":"94","author":"Johnson","year":"2009","journal-title":"Haematologica"},{"issue":"6","key":"2020062611393589200_B45","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1080\/10428194.2017.1387912","article-title":"Survival of patients with CD20-negative variants of large B-cell lymphoma: an analysis of the National Cancer Data Base","volume":"59","author":"Qunaj","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2020062611393589200_B46","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1038\/s41375-019-0691-6","article-title":"Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC\/BCL2 double-hit","volume":"34","author":"Cucco","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"2020062611393589200_B47","doi-asserted-by":"crossref","first-page":"362","DOI":"10.4049\/jimmunol.177.1.362","article-title":"The biological activity of human CD20 monoclonal antibodies is linked to unique epitopes on CD20","volume":"177","author":"Teeling","year":"2006","journal-title":"J Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/2886\/1746003\/advancesadv2020001696.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/13\/2886\/1746003\/advancesadv2020001696.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,27]],"date-time":"2020-06-27T03:43:50Z","timestamp":1593229430000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/13\/2886\/461125\/Genetic-and-evolutionary-patterns-of-treatment"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,26]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2020,7,14]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2020001696","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,26]]}}}